HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Beta Drugs Ltd Stock Comparison

Aurobindo Pharma Ltd vs Beta Drugs Ltd Stock Comparison

Last Updated on: Jun 27, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1123 as of 27 Jun 09:20.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Beta Drugs Ltd changed from 4.1 on March 2020 to 32.5 on March 2024 . This represents a CAGR of 51.29% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Beta Drugs Ltd changed from ₹ 38.46 crore on March 2020 to ₹ 1186 crore on March 2024 . This represents a CAGR of 98.53% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Mar '25 is ₹ 8516 crore as compare to the Dec '24 revenue of ₹ 8137 crore. This represent the growth of 4.66% The revenue of Beta Drugs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Aurobindo Pharma Ltd for the Mar '25 is ₹ 1894 crore as compare to the Dec '24 ebitda of ₹ 1736 crore. This represent the growth of 9.08% The ebitda of Beta Drugs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 902.83 crore over 8 quarters. This represents a CAGR of 25.89% The net profit of Beta Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Beta Drugs Ltd

  • Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
  • Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
  • Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
  • The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
  • The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma Ltd spurts 0.22%, up for fifth straight session

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs ...

Read more

26 Jun 2025 13:00

News

Aurobindo Pharma gets UK MHRA approval for neutropenia treatment drug Dyrupeg

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a ...

Read more

25 Jun 2025 12:51

News

CuraTeQ Biologics receives UK MHRA approval for biosimilar Dyrupeg'

Aurobindo Pharma announced that CuraTeQ Biologics s.r.o., a wholly owned step-down subsidi...

Read more

24 Jun 2025 19:01

News

Aurobindo Pharma Ltd down for fifth straight session

Aurobindo Pharma Ltd is down for a fifth straight session today. The stock is quoting at R...

Read more

17 Jun 2025 13:35

News

Aurobindo Pharma's US arm incorporates Cresedemo Pharma

The purpose of incorporating this new entity is to expand the company's pharmaceutical pro...

Read more

16 Jun 2025 08:40

News

Aurobindo Pharma incorporates WoS in USA

Aurobindo Pharma USA Inc. has incorporated a new wholly owned subsidiary in USA by the nam...

Read more

16 Jun 2025 10:34

Beta Drugs Ltd News Hub

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2025. Po...

Read more

10 May 2025 10:59

News

Beta Drugs announces board meeting date

Beta Drugs will hold a meeting of the Board of Directors of the Company on 27 March 2025. ...

Read more

20 Mar 2025 14:34

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 5 February 2025...

Read more

03 Feb 2025 10:49

News

Beta Drugs schedules EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

28 Nov 2024 15:41

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024...

Read more

04 Nov 2024 14:01

News

Beta Drugs to conduct EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

21 Oct 2024 13:59

SWOT Analysis Of Beta Drugs Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Beta Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Beta Drugs Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Beta Drugs Ltd?

Market cap of Aurobindo Pharma Ltd is 65,809 Cr while Market cap of Beta Drugs Ltd is 1,781 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Beta Drugs Ltd?

The stock performance of Aurobindo Pharma Ltd and Beta Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Beta Drugs Ltd?

As of June 27, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1123.15. On the other hand, Beta Drugs Ltd stock price is INR ₹1765.0.

How do dividend payouts of Aurobindo Pharma Ltd and Beta Drugs Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Beta Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions